Analysis of clinical outcome in patients with tAPL compared to de novo APL in the JALSG AML/MDS/CMML clinical observation study (JALSG-CS-07/11) -JALSG CS-07/11-tAPL study
Not Applicable
- Conditions
- de novo and therapy-related APL (acute promyelocytic leukemia)
- Registration Number
- JPRN-UMIN000044306
- Lead Sponsor
- Japan Adult Leukemia Study Group (JALSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 670
Inclusion Criteria
Not provided
Exclusion Criteria
For survival analysis, patients who did not receive chemotherapy-as-usual* for APL. *: Regimens including not hypomethylating agents but all-trans retinoic acid (ATRA), arsenic trioxide (ATO), or tamibarotene (Am80).
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival (OS) rates in patients*1 with t-APL and de novo APL, respectively.
- Secondary Outcome Measures
Name Time Method